Soleno Therapeutics (SLNO) Change in Acquisitions & Divestments (2024 - 2026)

Soleno Therapeutics (SLNO) has 3 years of Change in Acquisitions & Divestments data on file, last reported at $139.3 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 103.94% year-over-year to $139.3 million in Q1 2026; TTM through Mar 2026 was $325.1 million, a 63.1% increase from a year earlier, with the FY2025 full-year figure at $254.1 million, up 93.95% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $139.3 million, up from $62.5 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for SLNO reached as high as $139.3 million in Q1 2026 and fell as low as $25.0 million in Q2 2024.
• Historically, Change in Acquisitions & Divestments has averaged $65.5 million across 3 years, with a median of $58.3 million in 2024.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 106.0% in 2025 and fell as far as 15.81% in 2025.
• Year by year, Change in Acquisitions & Divestments stood at $54.0 million in 2024, then grew by 15.81% to $62.5 million in 2025, then jumped by 122.73% to $139.3 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $139.3 million in Q1 2026, $62.5 million in Q4 2025, and $71.7 million in Q3 2025.